Skip to main content
NCBI home page
The Brown Journal of Hospital Medicine logoLink to The Brown Journal of Hospital Medicine
. 2022 Aug 26;1(3):37850. doi: 10.56305/001c.37850

Diabetic Cardiomyopathy: Pathophysiology and Novel Therapies

Sidhi Laksono 1, Grace T Hosea 2, Zahra Nurusshofa 3
PMCID: PMC11878873  PMID: 40046584

Abstract

Diabetes mellitus and heart failure have a bidirectional relationship and can affect one another. Ventricular dysfunction that occurs in the absence of coronary atherosclerosis and hypertension in patients with diabetes mellitus is termed diabetic cardiomyopathy. Lipotoxicity, increased oxidative stress and mitochondrial dysfunction are a few of the mechanisms implicated in diabetic cardiomyopathy. Patients with diabetes mellitus undergo cardiac structural changes leading to heart failure. The novel glucose-lowering medication that is now preferred for diabetic patients with heart failure is the SGLT-2 (sodium-glucose cotransporter 2) inhibitor. Emerging targeted therapies are showing beneficial effects but require further evaluation. We review the literature describing the pathophysiology of diabetic cardiomyopathy, cardiac structural changes, along with the novel glucose-lowering therapies and targeted therapies for diabetic cardiomyopathy.

Keywords: Diabetes mellitus, heart failure, diabetic cardiomyopathy, targeted therapy, SGLT-2

Introduction

Diabetes mellitus (DM) is an independent risk factor for heart failure and there exists a bidirectional relationship between DM and heart failure (HF). The prevalence of heart failure in patients with DM is 4 times higher than in the general population.1 According to the Framingham Heart Study, cardiovascular disease (CVD) attributable to DM has increased over the past 50 years. Amongst other risk factors, only DM demonstrated an increase in the population attributable risk (PAR) for heart failure over the 2 time periods (1952 to 1974 and 1975 to 1998).2 The pathophysiology of heart failure preserved ejection fraction (HFpEF) is closely related to DM and approximately 40% of HFpEF patients have DM.3 Heart failure with reduced ejection fraction (HFrEF) is often associated with DM progression. HFrEF has a strong association with type 1 diabetes mellitus (T1DM).4

DM can cause various structural and functional changes in the myocardium. These changes are characterized by abnormal cardiac structure and function in the absence of other cardiac risk factors and was first reported in a postmortem study from diabetic patients who developed heart failure symptoms without evidence of coronary artery or valve disease. In 2013, the American College of Cardiology Foundation, the American Heart Association (ACC/AHA), and the European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD) defined diabetic cardiomyopathy as a clinical condition of ventricular dysfunction that occurs in the absence of coronary atherosclerosis and hypertension in patients with diabetes mellitus.5,6 In the early stages, some structural and functional changes occur, some of which are left ventricular (LV) hypertrophy, fibrosis, and cell signaling disruption.7 These changes evolve into HF and further into HFrEF. The goal of this review is to summarize current knowledge about diabetic cardiomyopathy, its current pathophysiology and novel treatments.

Methods

The research design of this study was a short narrative review. We conducted a literature search on diabetic cardiomyopathy and existing novel treatment from databases consisting of PubMed and Google Scholar. We found 465 literature search results with “diabetic cardiomyopathy” as a keyword and 36 literature search results with its “novel treatment”. We limited our research for literature written in the English language and for which the access to full text was available. The selection of the literature results reviewed in the manuscript was performed qualitatively by authors. Screening for duplicates was done automatically using citation manager software, Mendeley.

Results

Diabetes mellitus and Heart Failure

There is a strong association between DM and HF. There are 2 forms of heart failure described in DM: HFrEF (LVEF < 40%) and HFpEF (LVEF 41-49%). The prevalence of DM among patients with HFpEF is around 45%. A large cohort study of 1.9 million people with DM found that the most common CVD events were heart failure (14.1%) and peripheral arterial disease (PAD) (16.2%).8 Based on a population-based study in Reykjavik, impaired glucose regulation in diabetes mellitus is also associated with a risk of congestive heart failure. The prevalence of glucose abnormalities and heart failure increased with age. This study supports the suggestion that glucometabolic abnormalities confer risk for heart failure progression.9 While in T1DM, a cohort study found that a 1% increase in HbA1C (hemoglobin A1C) was associated with a 30% increased risk of developing HF, the risk of heart failure increased with several factors, such as age, duration of diabetes, and other factors.10

Patients with HF can also have an increased risk for new-onset DM. In a cohort study, HF severity was associated with a greater likelihood of developing DM.11 Another study reported that patients with a history of HF have a 2-fold increased risk of developing diabetes mellitus within 3-4 years independent of age, gender, and other comorbidities (e.g. hypertension). They suggest that HF may cause further worsening of DM status.12

The correlation between HF and DM is unclear, but there are possible explanations. Patients with HF have decreased cardiac output hence oxygen, insulin, and glucose distribution to peripheral tissue are also decreased. Due to impaired blood flow, adrenaline and noradrenaline levels are increased. The increased adrenaline and noradrenaline are suggested to increase insulin resistance and decrease insulin production in the pancreas.13 Cortisol and catecholamine hormones are also increased thus increasing the blood glucose level. Activation of the sympathetic systems stimulates gluconeogenesis and glycogenolysis. The increasing level of catecholamines can also cause insulin resistance.14

Pathophysiology of Diabetic Cardiomyopathy

Various mechanisms are thought to be responsible for heart failure associated with diabetes mellitus and it is not limited to diabetic cardiomyopathy. Abnormal extracellular matrix, lipotoxicity to the myocardium, increase in oxidative stress and inflammation, and mitochondrial dysfunction are some of the mechanisms causing heart failure. Increased levels of glucose residues and metabolites upregulate the production of advanced glycation end products (AGEs), which can affect cardiomyocytes and endothelial cells.15 Figure 1 outlines some of the mechanisms thought to contribute to diabetic cardiomyopathy.

Figure 1. Pathophysiologic mechanisms of diabetic cardiomyopathy.

Figure 1.

Open in a new tab

Free Fatty Acid Accumulation

Free fatty acids are increased due to diabetes mellitus and obesity accumulating in the adipose tissue mainly as triglycerides. Fatty acid intake and β-oxidation are increased to maintain sufficient levels of ATP production but overtime β-oxidation cannot adequately metabolize all incoming fatty acids resulting in the accumulation of free fatty acid (FFA).16 Ectopic fat that accumulates in organs other than the adipocytes of visceral fat and subcutaneous fat causes the dysfunction of cells and organs, such as the liver, pancreatic β cells, the skeletal muscle, and myocardium, through the deterioration of mitochondrial function. This condition is called lipotoxicity.17

Fat accumulation is present in the heart and in the myocardium. Pericardial fat is divided into two types, pericardial fat located on the outside and epicardial fat located on the inside. High epicardial fat mass has been reported to be an independent predictor of the development of coronary artery disease.17 The myocardial FFA build-up leads to decreased myocardial energy production, reduced myocyte contractility, and lipoapoptosis.18

Altered Calcium Signaling

Calcium (Ca2+) has a vital role in myocardial contraction. During an action potential, membrane depolarization-induced an initial Ca2+ signal so there is a Ca2+ influx to activate the Ca2+ channel and finally activate myofibrils to contract. In type 1 diabetes, there is a reduced Ca2+ influx due to reduced expression of sarcolemmal L type Ca2+ channels (LTCC) where Ca2+ ions pass through.19 The intracellular [Ca2+] is decreased as well as the systolic rate of [Ca2+] rise and decay.

In type 2 diabetes mellitus (T2DM), similar to T1DM, there is also a diminished LTCC density and Ca2+ current (ICa) density.20–23 Some studies also reported a depressed ryanodine receptor (RyR), a Ca2+ release channel.24–26 RyR activity can also be regulated during acute hyperglycemia. Hyperglycemia leads to O-Glc-NAcylation of proteins such as CaMKII which plays a key role in the regulation of excitation-contraction coupling. A recent study showed that a sudden increase of glucose or O-linked N-acetylglucosamine is directly responsible for CaMKII-dependent diastolic sarcoplasmic reticulum (SR) Ca2+ leak from the RyRs leading to consequent SR Ca2+ load depletion which is consistent with the increase of SR Ca2+ leak observed in different early stage of diabetes.27

Increased Oxidative stress

Chronic hyperglycemia leads to the generation of oxidative stress in pancreatic β-cells.28 Hyperglycemia promotes the overproduction of reactive oxygen species by the mitochondrial electron transport chain and exacerbates the formation of AGE.29,30 High glucose levels are metabolized into sorbitol through the polyol pathway with NADPH (nicotinamide adenine dinucleotide phosphate) and NAD+ (nicotinamide adenine dinucleotide). Increased activity of polyol pathway causing an elevation in NADH/NAD+ ratio that leads to overproduction of reactive oxygen species (ROS).31 AGEs have a dominant presence in the diabetic heart, and it is possible that AGE also has a role in the pathogenesis of diabetic cardiomyopathy. AGE receptor (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and the binding of ligands to RAGE stimulates various signaling pathways.32 The AGE-RAGE interaction stimulates NADPH oxidase-1 which contributes to reactive oxygen species production in diabetes.33 All this leads to cardiac fibrosis and hypertrophy.34 Hyperglycemia, oxidative stress, and the hexosamine biosynthetic pathway that provide substrate for proteoglycan synthesis and for O-linked glycosylation of certain proteins are associated with cardiomyocyte apoptosis.35

Mitochondrial Dysfunction

The heart is an organ that greatly depends on mitochondria as this organelle makes up to 1/3 of cardiac volume and produces adenosine triphosphate (ATP) from the oxidation of fatty acid and glucose.36 In a diabetic state where the insulin production or action is reduced, the mitochondria will use fatty acid as a source to make ATP instead of glucose which can also increase ROS.37 Dysfunctional calcium handling, where there is an excessive calcium influx or reduced calcium efflux can trigger the opening of mitochondrial permeability transition pore (mPTP), leading to mitochondrial dysfunction.38

Increased oxidative stress and mitochondrial dysfunction can cause cells, protein, and nucleic acid destructions that lead to cell apoptosis. The heart consumes large amounts of ATP therefore it has a rather low ATP reserve. In the pathological condition, however, fatty acids only provide 50-70% energy needed by the human heart.39 Mitochondria can switch the source of ATP production depending on the availability of the nutrients. Insulin also plays a role in this selection of energy sources.40 High consumption of ATP depletes the ATP reservoir, and low ATP production may lead to decreased cardiac function.41

Structural changes

Being in a chronic hyperglycemic state may alter the structure and function in the myocardium. In the patient with DM, there seems to be an increase in LV mass, and based on a study, a 1% rise in HbA1C level contributes to a 3.0 gr increase in LV mass, although further studies need to be done to assess the duration of elevated HbA1C that may contribute to the increased of LV mass.42 LV hypertrophy in patients with DM is mainly eccentric although both forms of hypertrophy can be present.43 As the disease progresses, remodeling can also shift from eccentric to concentric.44 Another hallmark of diabetic cardiomyopathy is left ventricular diastolic dysfunction.45,46 The initial characteristic of diastolic dysfunction in patients with DM are prolonged and delayed LV filling and LV relaxation.47

On a cellular level, an extracellular matrix (ECM) remodeling leads to myocardial fibrosis, usually in the later stage of the disease. In the early stage, myocytes appear to be hypertrophic rather than fibrotic.48 Collagen deposits can also be seen as a result of apoptotic myocyte death and impaired collagen degradation from glycosylation of lysine residues on collagen.49

Diagnosis

There are two stages of diabetic cardiomyopathy; the early stage is characterized by left ventricular concentric hypertrophy, increased myocardial stiffness, increase in atrial filling pressure, and impaired diastolic function; while the late stage is characterized by an increase in cardiac fibrosis, further impairment in diastolic function, and appearance of systolic dysfunction. There are no distinct criteria nor biochemical markers or physical characteristics for diagnosing diabetic cardiomyopathy. The pathological changes during the disease progress are often asymptomatic, so the only way to detect any changes regarding the disease is through further examination. Tissue doppler imaging and strain rate imaging may be used to assess LV dysfunction during stress testing. The ratio of the medial mitral annulus (e′) with early passive transmitral inflow velocity (E) has been shown to be a reliable index of left ventricular filling pressure and is a useful prognostic biomarker in diabetic patients.50

Although it is often said that patients with diabetic cardiomyopathy usually have diastolic dysfunction, examination using strain imaging and cardiac magnetic resonance (CMR) has detected a subtle presence of systolic dysfunction and reduced longitudinal contractility without discrete diastolic dysfunction.51 Magnetic resonance (MR) spectroscopy is a novel diagnostic tool that can identify myocardial metabolic changes, such as quantifying myocardial triglyceride content. Assessment of interstitial fibrosis and steatosis by using delayed gadolinium enhancement cardiac MRI is possible but it is still undergoing investigation.52

Novel glucose-lowering drugs for Heart Failure

As mentioned above, DM is associated with poor prognosis and longer hospitalization for HF. Thus, lowering the glycemic index has become a goal in heart failure treatment. New classes of antihyperglycemic drugs such as glucagon-like peptide-1 (GLP-1) analog and sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce cardiovascular mortality and improve glycemic control.53,54 However, the treatment of T2DM patients with HF using GLP-1 analogs remains controversial. Several studies in DM patients have found that GLP-1 analogs did not affect any major adverse cardiovascular event (MACE).55,56 Other trials showed that GLP-1 analogs have a significantly lower cardiovascular mortality rate, nonfatal myocardial infarction, or nonfatal stroke, improve lipotoxicity, and also protects cardiac function in T2DM patients.57–59 On the other hand, there are also studies that concluded the liraglutide (a GLP-1 analog) worsened the cardiac outcomes and significantly increase MACE.60,61

The EMPA-REG OUTCOME trial (The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes mellitus Patients–Removing Excess Glucose) showed that T2DM patients who received empagliflozin, a selective SGLT2i, have a lower rate cardiovascular mortality, hospitalization for heart failure, nonfatal myocardial infarction, or nonfatal stroke.62 Canagliflozin, another SGLT2i drug, also showed a significantly reduced risk of mortality due to cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke but had a greater risk of amputation.63 SGLT2i also have blood pressure (BP) lowering properties but are not as effective as other antihypertensive drugs such as angiotensin-converting enzyme (ACE) inhibitors.64 It is found that empagliflozin was associated with reduced systolic and diastolic blood pressure compared with placebo (who received an additional glucose-lowering medicine and also antihypertensive medicine, including diuretics).62 On the other hand, there was no significant difference in systolic and diastolic blood pressure in the use of Canagliflozin compared to placebo.63 SGLT2i worked proportionally with the ambient glucose concentration, hence it may have a greater effect on individuals with poor glycemic control. However, the effect of SGLT2i on blood pressure doesn’t seem to be consistent with the blood glucose level, lowering systolic 4-6 mmHg and diastolic 1-2mmHg.64

The incretin-based drugs such as dipeptidyl peptidase-4 (DPP-4) inhibitors have no beneficial effect on HF but were shown to reduce the occurrence of hepatic steatosis.65,66 Other trials have shown that DPP-4 inhibitor was not superior to placebo.67–69 The ESC-EASD 2019 guideline only recommends DPP-4 inhibitors when HbA1C targets are not reached after using SGLT2i, metformin, and/or GLP-1 receptor agonists.70 The DPP-4 inhibitor that is not recommended for patients with or with risk of HF is saxagliptin as it can increase the risk for hospitalization for HF (HHF) and also increase the HF incidence in T2DM patients.71

Novel Targeted therapies for diabetic cardiomyopathy

MicroRNA (miRNA) is reported to have a role in the pathophysiology of diabetic cardiomyopathy, such as increase ROS production and promote cardiomyocyte apoptosis.72–75 Anti-miRNA and miRNA mimics are actively studied and developed to treat cardiomyopathy.76–78 Antioxidant therapies can be used for prevention and intervention for diabetic cardiomyopathy.79–85 Phenolic acids are beneficial for mitochondrial dysfunction as the protective agent of the heart against mitochondrial dysfunction and are obtained from plants such as nuts and fruits and thus can be added to the diets.86 Bile Acids are synthesized by cholesterol, bind and activate Farnesoid X Receptor (FXR) that leads to reduction of inflammation and have a regulatory effect on autophagy and mitochondrial function and can also suppress oxidative stress that showing a potential therapeutic effect.87 However further studies are still ongoing.

Conclusion

There is a strong association between diabetes mellitus and heart failure incidence. Patients with heart failure have increased risk for new-onset DM. The proposed mechanisms underlying the pathophysiology of diabetic cardiomyopathy include lipotoxicity related to free fattty acid accumulation, altered calcium signaling, increased oxidative stress due to chronic hyperglycemia leading to mitochondrial dysfunction and alteration of structure and function in the myocardium. SGLT2i and novel targeted therapies for diabetic cardiomyopathy are promising treatments but require further investigation. It is important for clinicians to be aware of diabetic cardiomyopathy in order to improve cardiovascular outcomes in diabetes mellitus.

Conflicts of interest

There are no conflicts of interest among any of the authors and received no specific support for this work.

Corresponding author

Sidhi Laksono, MD

Faculty of Medicine, Universitas Muhammadiyah Prof. Dr. Hamka

Jl. Limau II No.2, RT.3/RW.3, Kramat Pela, Kec. Kby. Baru, Kota Jakarta Selatan, Daerah Khusus Ibukota Jakarta 12130, Indonesia

E-mail: sidhilaksono@uhamka.ac.id

References

  1. The incidence of congestive heart failure in type 2 diabetes: an update. Nichols Gregory A., Gullion Christina M., Koro Carol E., Ephross Sara A., Brown Jonathan B. Aug 1;2004 Diabetes care. 27(8):1879–1884. doi: 10.2337/diacare.27.8.1879. https://doi.org/10.2337/diacare.27.8.1879 [DOI] [PubMed] [Google Scholar]
  2. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Fox Caroline S., Coady Sean, Sorlie Paul D., D’Agostino Ralph B. Sr, Pencina Michael J., Vasan Ramachandran S., Meigs James B., Levy Daniel, Savage Peter J. Mar 27;2007 Circulation. 115(12):1544–1550. doi: 10.1161/circulationaha.106.658948. https://doi.org/10.1161/circulationaha.106.658948 [DOI] [PubMed] [Google Scholar]
  3. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Paulus Walter J., Tschöpe Carsten. Jul;2013 Journal of the American College of Cardiology. 62(4):263–271. doi: 10.1016/j.jacc.2013.02.092. https://doi.org/10.1016/j.jacc.2013.02.092 [DOI] [PubMed] [Google Scholar]
  4. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Seferović Petar M., Paulus Walter J. Apr 17;2015 European heart journal. 36(27):1718–1727. doi: 10.1093/eurheartj/ehv134. https://doi.org/10.1093/eurheartj/ehv134 [DOI] [PubMed] [Google Scholar]
  5. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey Donald E. Jr, Drazner Mark H., Fonarow Gregg C., Geraci Stephen A., Horwich Tamara, Januzzi James L., Johnson Maryl R., Kasper Edward K., Levy Wayne C., Masoudi Frederick A., McBride Patrick E., McMurray John J.V., Mitchell Judith E., Peterson Pamela N., Riegel Barbara, Sam Flora, Stevenson Lynne W., Tang W.H. Wilson, Tsai Emily J., Wilkoff Bruce L. Oct 15;2013 Circulation. 62(16):e147–239. doi: 10.1161/cir.0b013e31829e8776. https://doi.org/10.1161/cir.0b013e31829e8776 [DOI] [PubMed] [Google Scholar]
  6. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Cosentino F., Grant P.J., Aboyans V., et al. Aug 30;2013 European Heart Journal. 34(39):3035–3087. doi: 10.1093/eurheartj/eht108. https://doi.org/10.1093/eurheartj/eht108 [DOI] [PubMed] [Google Scholar]
  7. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Jia Guanghong, Hill Michael A., Sowers James R. Feb 16;2018 Circulation Research. 122(4):624–638. doi: 10.1161/circresaha.117.311586. https://doi.org/10.1161/circresaha.117.311586 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Shah Anoop Dinesh, Langenberg Claudia, Rapsomaniki Eleni, Denaxas Spiros, Pujades-Rodriguez Mar, Gale Chris P, Deanfield John, Smeeth Liam, Timmis Adam, Hemingway Harry. Feb;2015 The Lancet Diabetes & Endocrinology. 3(2):105–113. doi: 10.1016/s2213-8587(14)70219-0. https://doi.org/10.1016/s2213-8587(14)70219-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Thrainsdottir Inga S., Aspelund Thor, Thorgeirsson Gudmundur, Gudnason Vilmundur, Hardarson Thordur, Malmberg Klas, Sigurdsson Gunnar, Rydén Lars. Mar 1;2005 Diabetes care. 28(3):612–616. doi: 10.2337/diacare.28.3.612. https://doi.org/10.2337/diacare.28.3.612 [DOI] [PubMed] [Google Scholar]
  10. Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study. Lind Marcus, Bounias Ioannis, Olsson Marita, Gudbjörnsdottir Soffia, Svensson Ann-Marie, Rosengren Annika. Jul;2011 The Lancet. 378(9786):140–146. doi: 10.1016/s0140-6736(11)60471-6. https://doi.org/10.1016/s0140-6736(11)60471-6 [DOI] [PubMed] [Google Scholar]
  11. Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study. Demant Malene N., Gislason Gunnar H., Køber Lars, Vaag Allan, Torp-Pedersen Christian, Andersson Charlotte. May 22;2014 Diabetologia. 57(8):1595–1600. doi: 10.1007/s00125-014-3259-z. https://doi.org/10.1007/s00125-014-3259-z [DOI] [PubMed] [Google Scholar]
  12. Heart failure as a risk factor for diabetes mellitus. Guglin Maya, Lynch Kristian, Krischer Jeffrey. 2014Cardiology. 129(2):84–92. doi: 10.1159/000363282. https://doi.org/10.1159/000363282 [DOI] [PubMed] [Google Scholar]
  13. The association of heart failure with insulin resistance and the development of type 2 diabetes. Kostis J, Sanders M. May;2005 American journal of hypertension. 18(5):731–737. doi: 10.1016/j.amjhyper.2004.11.038. https://doi.org/10.1016/j.amjhyper.2004.11.038 [DOI] [PubMed] [Google Scholar]
  14. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry. Benedict Claude R., Weiner Debra H., Johnstone David E., Bourassa Martial G., Ghali Jalal K., Nicklas John, Kirlin Philip, Greenberg Barry, Quinones Miguel A., Yusuf Salim. Oct;1993 Journal of the American College of Cardiology. 22(4):A146–A153. doi: 10.1016/0735-1097(93)90480-o. https://doi.org/10.1016/0735-1097(93)90480-o [DOI] [PubMed] [Google Scholar]
  15. Advanced glycation end products in children with type 1 diabetes and early reduced diastolic heart function. Brunvand Leif, Heier Martin, Brunborg Cathrine, Hanssen Kristian F., Fugelseth Drude, Stensaeth Knut Haakon, Dahl-Jørgensen Knut, Margeirsdottir Hanna Dis. May 25;2017 BMC cardiovascular disorders. 17(1):1–6. doi: 10.1186/s12872-017-0551-0. https://doi.org/10.1186/s12872-017-0551-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. The role of inflammation in diabetic cardiomyopathy. Nunes S., Soares E., Pereira F., Reis F. 2012Int J Infereron Cytokine Mediator Res. 4:59–73. [Google Scholar]
  17. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. Mahabadi Amir A., Berg Marie H., Lehmann Nils, Kälsch Hagen, Bauer Marcus, Kara Kaffer, Dragano Nico, Moebus Susanne, Jöckel Karl-Heinz, Erbel Raimund, Möhlenkamp Stefan. Apr;2013 Journal of the American College of Cardiology. 61(13):1388–1395. doi: 10.1016/j.jacc.2012.11.062. https://doi.org/10.1016/j.jacc.2012.11.062 [DOI] [PubMed] [Google Scholar]
  18. Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. Pappachan Joseph M, Varughese George I, Sriraman Rajagopalan, Arunagirinathan Ganesan. 2013World journal of diabetes. 4(5):177. doi: 10.4239/wjd.v4.i5.177. https://doi.org/10.4239/wjd.v4.i5.177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Decreased L-type Ca2+ current in cardiac myocytes of type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling. Lu Zhongju, Jiang Ya-Ping, Xu Xin-Hua, Ballou Lisa M., Cohen Ira S., Lin Richard Z. Nov 1;2007 Diabetes. 56(11):2780–2789. doi: 10.2337/db06-1629. https://doi.org/10.2337/db06-1629 [DOI] [PubMed] [Google Scholar]
  20. Mechanisms of [Ca2+] i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Pereira Laetitia, Matthes Jan, Schuster Iris, Valdivia Héctor H., Herzig Stefan, Richard Sylvain, Gómez Ana M. Mar 1;2006 Diabetes. 55(3):608–615. doi: 10.2337/diabetes.55.03.06.db05-1284. https://doi.org/10.2337/diabetes.55.03.06.db05-1284 [DOI] [PubMed] [Google Scholar]
  21. Changing pattern of gene expression is associated with ventricular myocyte dysfunction and altered mechanisms of Ca2+signalling in young type 2 Zucker diabetic fatty rat heart. Howarth F. C., Qureshi M. A., Hassan Z., Al Kury L. T., Isaev D., Parekh K., Yammahi S. R. K. D., Oz M., Adrian T. E., Adeghate E. Jan 28;2011 Experimental Physiology. 96(3):325–337. doi: 10.1113/expphysiol.2010.055574. https://doi.org/10.1113/expphysiol.2010.055574 [DOI] [PubMed] [Google Scholar]
  22. Contractility of ventricular myocytes is well preserved despite altered mechanisms of Ca2+ transport and a changing pattern of mRNA in aged type 2 Zucker diabetic fatty rat heart. Howarth F. C., Qureshi M. A., Hassan Z., Isaev D., Parekh K., John A., Oz M., Raza H., Adeghate E., Adrian T. E. Oct 19;2012 Molecular and cellular biochemistry. 361(1):267–280. doi: 10.1007/s11010-011-1112-y. https://doi.org/10.1007/s11010-011-1112-y [DOI] [PubMed] [Google Scholar]
  23. Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-ι. Lu Zhongju, Ballou Lisa M, Jiang Ya-Ping, Cohen Ira S, Lin Richard Z. Oct;2011 Journal of cardiovascular pharmacology. 58(4):439–445. doi: 10.1097/fjc.0b013e318228e68c. https://doi.org/10.1097/fjc.0b013e318228e68c [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Effects of diabetes on ryanodine receptor Ca release channel (RyR2) and Ca2+ homeostasis in rat heart. Yaras Nazmi, Ugur Mehmet, Ozdemir Semir, Gurdal Hakan, Purali Nuhan, Lacampagne Alain, Vassort Guy, Turan Belma. Nov 1;2005 Diabetes. 54(11):3082–3088. doi: 10.2337/diabetes.54.11.3082. https://doi.org/10.2337/diabetes.54.11.3082 [DOI] [PubMed] [Google Scholar]
  25. Decrease in calcium-sensing receptor in the progress of diabetic cardiomyopathy. Bai Shu Zhi, Sun Jian, Wu Hao, Zhang Ning, Li Hong-xia, Li Guang-wei, Li Hong-zhu, He Wen, Zhang Wei-hua, Zhao Ya-jun, Wang Li-na, Tian Ye, Yang Bao-feng, Yang Guang-dong, Wu Ling-yun, Wang Rui, Xu Chang-qing. Mar;2012 Diabetes research and clinical practice. 95(3):378–385. doi: 10.1016/j.diabres.2011.11.007. https://doi.org/10.1016/j.diabres.2011.11.007 [DOI] [PubMed] [Google Scholar]
  26. Chronic diabetes alters function and expression of ryanodine receptor calcium-release channels in rat hearts. Bidasee Keshore R., Nallani Karuna, Henry Bruce, Dincer U. Deniz, Besch Henry R. Jr. 2003Biochemistry of Diabetes and Atherosclerosis. 113-23:113–123. doi: 10.1007/978-1-4419-9236-9_15. https://doi.org/10.1007/978-1-4419-9236-9_15 [DOI] [PubMed] [Google Scholar]
  27. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Erickson Jeffrey R., Pereira Laetitia, Wang Lianguo, Han Guanghui, Ferguson Amanda, Dao Khanha, Copeland Ronald J., Despa Florin, Hart Gerald W., Ripplinger Crystal M., Bers Donald M. Sep 29;2013 Nature. 502(7471):372–376. doi: 10.1038/nature12537. https://doi.org/10.1038/nature12537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Lenzen Slgurd, Drinkgern Jens, Tiedge Markus. Jan;1996 Free Radical Biology and Medicine. 20(3):463–466. doi: 10.1016/0891-5849(96)02051-5. https://doi.org/10.1016/0891-5849(96)02051-5 [DOI] [PubMed] [Google Scholar]
  29. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Yuan Ting, Yang Ting, Chen Huan, Fu Danli, Hu Yangyang, Wang Jing, Yuan Qing, Yu Hong, Xu Wenfeng, Xie Xiang. Jan;2019 Redox biology. 20:247–260. doi: 10.1016/j.redox.2018.09.025. https://doi.org/10.1016/j.redox.2018.09.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Biochemistry and molecular cell biology of diabetic complications. Brownlee Michael. Dec 13;2001 Nature. 414(6865):813–820. doi: 10.1038/414813a. https://doi.org/10.1038/414813a [DOI] [PubMed] [Google Scholar]
  31. Aldose reductase, oxidative stress and diabetic cardiovascular complications. Vedantham Srinivasan, Ananthakrishnan Radha, Marie Schmidt Ann, Ramasamy Ravichandran. Jul 1;2012 Cardiovascular & Hematological Agents in Medicinal Chemistry. 10(3):234–240. doi: 10.2174/187152512802651097. https://doi.org/10.2174/187152512802651097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Understanding RAGE, the receptor for advanced glycation end products. Bierhaus Angelika, Humpert Per M., Morcos Michael, Wendt Thoralf, Chavakis Triantafyllos, Arnold Bernd, Stern David M., Nawroth Peter P. Aug 24;2005 Journal of molecular medicine. 83(11):876–886. doi: 10.1007/s00109-005-0688-7. https://doi.org/10.1007/s00109-005-0688-7 [DOI] [PubMed] [Google Scholar]
  33. Advanced glycation endproducts induce apoptosis of endothelial progenitor cells by activating receptor RAGE and NADPH oxidase/JNK signaling axis. Chen J., Jing J., Yu S., Song M., Tan H., Cui B., Huang L. 2016American journal of translational research. 8(5):2169. [PMC free article] [PubMed] [Google Scholar]
  34. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Faria Alyssa, Persaud Shanta J. Apr;2017 Pharmacology & Therapeutics. 172:50–62. doi: 10.1016/j.pharmthera.2016.11.013. https://doi.org/10.1016/j.pharmthera.2016.11.013 [DOI] [PubMed] [Google Scholar]
  35. Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Rajamani Uthra, Essop M. Faadiel. Jul;2010 American Journal of Physiology-Cell Physiology. 299(1):C139–C147. doi: 10.1152/ajpcell.00020.2010. https://doi.org/10.1152/ajpcell.00020.2010 [DOI] [PubMed] [Google Scholar]
  36. Mitochondrial dysfunction in pathophysiology of heart failure. Zhou Bo, Tian Rong. Aug 20;2018 Journal of Clinical Investigation. 128(9):3716–3726. doi: 10.1172/jci120849. https://doi.org/10.1172/jci120849 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Jia Guanghong, Habibi Javad, DeMarco Vincent G., Martinez-Lemus Luis A., Ma Lixin, Whaley-Connell Adam T., Aroor Annayya R., Domeier Timothy L., Zhu Yi, Meininger Gerald A., Barrett Mueller Katelee, Jaffe Iris Z., Sowers James R. Dec;2015 Hypertension. 66(6):1159–1167. doi: 10.1161/hypertensionaha.115.06015. https://doi.org/10.1161/hypertensionaha.115.06015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Altered myocardial calcium cycling and energetics in heart failure—a rational approach for disease treatment. Gorski Przemek A., Ceholski Delaine K., Hajjar Roger J. Feb;2015 Cell metabolism. 21(2):183–194. doi: 10.1016/j.cmet.2015.01.005. https://doi.org/10.1016/j.cmet.2015.01.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Role of fatty acid uptake and fatty acid β-oxidation in mediating insulin resistance in heart and skeletal muscle. Zhang Liyan, Keung Wendy, Samokhvalov Victor, Wang Wei, Lopaschuk Gary D. Jan;2010 Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1801(1):1–22. doi: 10.1016/j.bbalip.2009.09.014. https://doi.org/10.1016/j.bbalip.2009.09.014 [DOI] [PubMed] [Google Scholar]
  40. Rationale for a metabolic approach in diabetic coronary patients. Stanley William C. Nov;2005 Coronary artery disease. 16:S11–S15. doi: 10.1097/00019501-200511001-00003. https://doi.org/10.1097/00019501-200511001-00003 [DOI] [PubMed] [Google Scholar]
  41. Cardiac performance is limited by oxygen delivery to the mitochondria in the crystalloid-perfused working heart. Kuzmiak-Glancy Sarah, Covian Raúl, Femnou Armel N., Glancy Brian, Jaimes Rafael III, Wengrowski Anastasia M., Garrott Kara, French Stephanie A., Balaban Robert S., Kay Matthew W. Apr 1;2018 American Journal of Physiology-Heart and Circulatory Physiology. 314(4):H704–H715. doi: 10.1152/ajpheart.00321.2017. https://doi.org/10.1152/ajpheart.00321.2017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. Skali H., Shah A., Gupta D.K., Cheng S., Claggett B., Liu J., Bello N., Aguilar D., Vardeny O., Matsushita K., Selvin E. 2015Circulation: Heart Failure. 8(3):448–454. doi: 10.1161/CIRCHEARTFAILURE.114.001990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. Bluemke David A., Kronmal Richard A., Lima João A.C., Liu Kiang, Olson Jean, Burke Gregory L., Folsom Aaron R. Dec;2008 Journal of the American College of Cardiology. 52(25):2148–2155. doi: 10.1016/j.jacc.2008.09.014. https://doi.org/10.1016/j.jacc.2008.09.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Progression of functional and structural cardiac alterations in young normotensive uncomplicated patients with type 1 diabetes mellitus. Carugo Stefano, Giannattasio Cristina, Calchera Ivan, Paleari Felice, Gorgoglione Maria Grazia, Grappiolo Alessandra, Gamba Pierluigi, Rovaris Giovanni, Failla Monica, Mancia Giuseppe. Sep;2001 Journal of hypertension. 19(9):1675–1680. doi: 10.1097/00004872-200109000-00021. https://doi.org/10.1097/00004872-200109000-00021 [DOI] [PubMed] [Google Scholar]
  45. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Boyer John K, Thanigaraj Srihari, Schechtman Kenneth B, Pérez Julio E. Apr;2004 The American journal of cardiology. 93(7):870–875. doi: 10.1016/j.amjcard.2003.12.026. https://doi.org/10.1016/j.amjcard.2003.12.026 [DOI] [PubMed] [Google Scholar]
  46. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Huynh Karina, Bernardo Bianca C., McMullen Julie R., Ritchie Rebecca H. Jun;2014 Pharmacology & Therapeutics. 142(3):375–415. doi: 10.1016/j.pharmthera.2014.01.003. https://doi.org/10.1016/j.pharmthera.2014.01.003 [DOI] [PubMed] [Google Scholar]
  47. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F., Dokainish H., Edvardsen T., Flachskampf F.A., Gillebert T.C., Klein A.L., Lancellotti P., Marino P. 2016European Journal of Echocardiography. 17(12):1321–1360. doi: 10.1093/ehjci/jew082. [DOI] [PubMed] [Google Scholar]
  48. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. van Heerebeek Loek, Hamdani Nazha, Handoko M. Louis, Falcao-Pires Ines, Musters René J., Kupreishvili Koba, Ijsselmuiden Alexander J.J., Schalkwijk Casper G., Bronzwaer Jean G.F., Diamant Michaela, Borbély Attila, van der Velden Jolanda, Stienen Ger J.M., Laarman Gerrit J., Niessen Hans W.M., Paulus Walter J. Jan;2008 Circulation. 117(1):43–51. doi: 10.1161/circulationaha.107.728550. https://doi.org/10.1161/circulationaha.107.728550 [DOI] [PubMed] [Google Scholar]
  49. Myocyte death and growth in the failing heart. Anversa P. 1998Lab Invest. 78:767–86. [PubMed] [Google Scholar]
  50. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Di Bonito P., Moio N., Cavuto L., Covino G., Murena E., Scilla C., Turco S., Capaldo B., Sibilio G. Dec;2005 Diabetic Medicine. 22(12):1720–1725. doi: 10.1111/j.1464-5491.2005.01685.x. https://doi.org/10.1111/j.1464-5491.2005.01685.x [DOI] [PubMed] [Google Scholar]
  51. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? Ernande Laura, Bergerot Cyrille, Rietzschel Ernst R., De Buyzere Marc L., Thibault Hélène, PignonBlanc Pierre Gautier, Croisille Pierre, Ovize Michel, Groisne Laure, Moulin Philippe, Gillebert Thierry C., Derumeaux Geneviève. Nov;2011 Journal of the American Society of Echocardiography. 24(11):1268–1275. doi: 10.1016/j.echo.2011.07.017. https://doi.org/10.1016/j.echo.2011.07.017 [DOI] [PubMed] [Google Scholar]
  52. In vivotargeted molecular magnetic resonance imaging of free radicals in diabetic cardiomyopathy within mice. Towner R. A., Smith N., Saunders D., Carrizales J., Lupu F., Silasi-Mansat R., Ehrenshaft M., Mason R. P. Jun;2015 Free Radical Research. 49(9):1140–1146. doi: 10.3109/10715762.2015.1050587. https://doi.org/10.3109/10715762.2015.1050587 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Liraglutide and cardiovascular outcomes in type 2 diabetes. Marso Steven P., Daniels Gilbert H., Brown-Frandsen Kirstine, Kristensen Peter, Mann Johannes F.E., Nauck Michael A., Nissen Steven E., Pocock Stuart, Poulter Neil R., Ravn Lasse S., Steinberg William M., Stockner Mette, Zinman Bernard, Bergenstal Richard M., Buse John B. Jul 28;2016 New England Journal of Medicine. 375(4):311–322. doi: 10.1056/nejmoa1603827. https://doi.org/10.1056/nejmoa1603827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zinman Bernard, Wanner Christoph, Lachin John M., Fitchett David, Bluhmki Erich, Hantel Stefan, Mattheus Michaela, Devins Theresa, Johansen Odd Erik, Woerle Hans J., Broedl Uli C., Inzucchi Silvio E. Nov 26;2015 New England Journal of Medicine. 373(22):2117–2128. doi: 10.1056/nejmoa1504720. https://doi.org/10.1056/nejmoa1504720 [DOI] [PubMed] [Google Scholar]
  55. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. Holman Rury R., Bethel M. Angelyn, Mentz Robert J., Thompson Vivian P., Lokhnygina Yuliya, Buse John B., Chan Juliana C., Choi Jasmine, Gustavson Stephanie M., Iqbal Nayyar, Maggioni Aldo P., Marso Steven P., Öhman Peter, Pagidipati Neha J., Poulter Neil, Ramachandran Ambady, Zinman Bernard, Hernandez Adrian F. Sep 28;2017 New England Journal of Medicine. 377(13):1228–1239. doi: 10.1056/nejmoa1612917. https://doi.org/10.1056/nejmoa1612917 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. Pfeffer Marc A., Claggett Brian, Diaz Rafael, Dickstein Kenneth, Gerstein Hertzel C., Køber Lars V., Lawson Francesca C., Ping Lin, Wei Xiaodan, Lewis Eldrin F., Maggioni Aldo P., McMurray John J.V., Probstfield Jeffrey L., Riddle Matthew C., Solomon Scott D., Tardif Jean-Claude. Dec 3;2015 New England Journal of Medicine. 373(23):2247–2257. doi: 10.1056/nejmoa1509225. https://doi.org/10.1056/nejmoa1509225 [DOI] [PubMed] [Google Scholar]
  57. Liraglutide and cardiovascular outcomes in type 2 diabetes. Marso Steven P., Daniels Gilbert H., Brown-Frandsen Kirstine, Kristensen Peter, Mann Johannes F.E., Nauck Michael A., Nissen Steven E., Pocock Stuart, Poulter Neil R., Ravn Lasse S., Steinberg William M., Stockner Mette, Zinman Bernard, Bergenstal Richard M., Buse John B. Jul 28;2016 New England Journal of Medicine. 375(4):311–322. doi: 10.1056/nejmoa1603827. https://doi.org/10.1056/nejmoa1603827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Marso Steven P., Bain Stephen C., Consoli Agostino, Eliaschewitz Freddy G., Jódar Esteban, Leiter Lawrence A., Lingvay Ildiko, Rosenstock Julio, Seufert Jochen, Warren Mark L., Woo Vincent, Hansen Oluf, Holst Anders G., Pettersson Jonas, Vilsbøll Tina. Nov 10;2016 New England Journal of Medicine. 375(19):1834–1844. doi: 10.1056/nejmoa1607141. https://doi.org/10.1056/nejmoa1607141 [DOI] [PubMed] [Google Scholar]
  59. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway. Wu Lujin, Wang Ke, Wang Wei, Wen Zheng, Wang Peihua, Liu Lei, Wang Dao Wen. Apr 16;2018 Aging Cell. 17(4):e12763. doi: 10.1111/acel.12763. https://doi.org/10.1111/acel.12763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. Margulies Kenneth B., Hernandez Adrian F., Redfield Margaret M., Givertz Michael M., Oliveira Guilherme H., Cole Robert, Mann Douglas L., Whellan David J., Kiernan Michael S., Felker G. Michael, McNulty Steven E., Anstrom Kevin J., Shah Monica R., Braunwald Eugene, Cappola Thomas P., for the NHLBI Heart Failure Clinical Research Network Aug 2;2016 Jama. 316(5):500. doi: 10.1001/jama.2016.10260. https://doi.org/10.1001/jama.2016.10260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Jorsal Anders, Kistorp Caroline, Holmager Pernille, Tougaard Rasmus Stilling, Nielsen Roni, Hänselmann Anja, Nilsson Brian, Møller Jacob Eifer, Hjort Jakob, Rasmussen Jon, Boesgaard Trine Welløv, Schou Morten, Videbæk Lars, Gustafsson Ida, Flyvbjerg Allan, Wiggers Henrik, Tarnow Lise. Oct 28;2017 European journal of heart failure. 19(1):69–77. doi: 10.1002/ejhf.657. https://doi.org/10.1002/ejhf.657 [DOI] [PubMed] [Google Scholar]
  62. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zinman Bernard, Wanner Christoph, Lachin John M., Fitchett David, Bluhmki Erich, Hantel Stefan, Mattheus Michaela, Devins Theresa, Johansen Odd Erik, Woerle Hans J., Broedl Uli C., Inzucchi Silvio E. Nov 26;2015 New England Journal of Medicine. 373(22):2117–2128. doi: 10.1056/nejmoa1504720. https://doi.org/10.1056/nejmoa1504720 [DOI] [PubMed] [Google Scholar]
  63. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Neal Bruce, Perkovic Vlado, Mahaffey Kenneth W., De Zeeuw Dick, Fulcher Greg, Erondu Ngozi, Shaw Wayne, Law Gordon, Desai Mehul, Matthews David R. Aug 17;2017 New England Journal of Medicine. 377(7):644–657. doi: 10.1056/nejmoa1611925. https://doi.org/10.1056/nejmoa1611925 [DOI] [Google Scholar]
  64. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Thomas Merlin C., Cherney David Z. Aug 22;2018 Diabetologia. 61(10):2098–2107. doi: 10.1007/s00125-018-4669-0. https://doi.org/10.1007/s00125-018-4669-0 [DOI] [PubMed] [Google Scholar]
  65. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. Scirica Benjamin M., Bhatt Deepak L., Braunwald Eugene, Steg P. Gabriel, Davidson Jaime, Hirshberg Boaz, Ohman Peter, Frederich Robert, Wiviott Stephen D., Hoffman Elaine B., Cavender Matthew A., Udell Jacob A., Desai Nihar R., Mosenzon Ofri, McGuire Darren K., Ray Kausik K., Leiter Lawrence A., Raz Itamar. Oct 3;2013 New England Journal of Medicine. 369(14):1317–1326. doi: 10.1056/nejmoa1307684. https://doi.org/10.1056/nejmoa1307684 [DOI] [PubMed] [Google Scholar]
  66. Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. Abdesselam Inès, Pepino Pauline, Troalen Thomas, Macia Michael, Ancel Patricia, Masi Brice, Fourny Natacha, Gaborit Bénédicte, Giannesini Benoît, Kober Frank, Dutour Anne, Bernard Monique. Nov 6;2015 Journal of Cardiovascular Magnetic Resonance. 17(1):1–5. doi: 10.1186/s12968-015-0198-x. https://doi.org/10.1186/s12968-015-0198-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Zannad Faiez, Cannon Christopher P, Cushman William C, Bakris George L, Menon Venu, Perez Alfonso T, Fleck Penny R, Mehta Cyrus R, Kupfer Stuart, Wilson Craig, Lam Hung, White William B. May;2015 The Lancet. 385(9982):2067–2076. doi: 10.1016/s0140-6736(14)62225-x. https://doi.org/10.1016/s0140-6736(14)62225-x [DOI] [PubMed] [Google Scholar]
  68. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. Green Jennifer B., Bethel M. Angelyn, Armstrong Paul W., Buse John B., Engel Samuel S., Garg Jyotsna, Josse Robert, Kaufman Keith D., Koglin Joerg, Korn Scott, Lachin John M., McGuire Darren K., Pencina Michael J., Standl Eberhard, Stein Peter P., Suryawanshi Shailaja, Van de Werf Frans, Peterson Eric D., Holman Rury R. Jul 16;2015 New England Journal of Medicine. 373(3):232–242. doi: 10.1056/nejmoa1501352. https://doi.org/10.1056/nejmoa1501352 [DOI] [PubMed] [Google Scholar]
  69. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Standl Eberhard, Schnell Oliver, McGuire Darren K. May 27;2016 Circulation research. 118(11):1830–1843. doi: 10.1161/circresaha.116.306924. https://doi.org/10.1161/circresaha.116.306924 [DOI] [PubMed] [Google Scholar]
  70. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Cosentino Francesco, Grant Peter J, Aboyans Victor, Bailey Clifford J, Ceriello Antonio, Delgado Victoria, Federici Massimo, Filippatos Gerasimos, Grobbee Diederick E, Hansen Tina Birgitte, Huikuri Heikki V, Johansson Isabelle, Jüni Peter, Lettino Maddalena, Marx Nikolaus, Mellbin Linda G, Östgren Carl J, Rocca Bianca, Roffi Marco, Sattar Naveed, Seferović Petar M, Sousa-Uva Miguel, Valensi Paul, Wheeler David C, Piepoli Massimo Francesco, Birkeland Kåre I, Adamopoulos Stamatis, Ajjan Ramzi, Avogaro Angelo, Baigent Colin, Brodmann Marianne, Bueno Héctor, Ceconi Claudio, Chioncel Ovidiu, Coats Andrew, Collet Jean-Philippe, Collins Peter, Cosyns Bernard, Di Mario Carlo, Fisher Miles, Fitzsimons Donna, Halvorsen Sigrun, Hansen Dominique, Hoes Arno, Holt Richard I G, Home Philip, Katus Hugo A, Khunti Kamlesh, Komajda Michel, Lambrinou Ekaterini, Landmesser Ulf, Lewis Basil S, Linde Cecilia, Lorusso Roberto, Mach François, Mueller Christian, Neumann Franz-Josef, Persson Frederik, Petersen Steffen E, Petronio Anna Sonia, Richter Dimitrios J, Rosano Giuseppe M C, Rossing Peter, Rydén Lars, Shlyakhto Evgeny, Simpson Iain A, Touyz Rhian M, Wijns William, Wilhelm Matthias, Williams Bryan, Aboyans Victor, Bailey Clifford J, Ceriello Antonio, Delgado Victoria, Federici Massimo, Filippatos Gerasimos, Grobbee Diederick E, Hansen Tina Birgitte, Huikuri Heikki V, Johansson Isabelle, Jüni Peter, Lettino Maddalena, Marx Nikolaus, Mellbin Linda G, Östgren Carl J, Rocca Bianca, Roffi Marco, Sattar Naveed, Seferović Petar M, Sousa-Uva Miguel, Valensi Paul, Wheeler David C, Windecker Stephan, Aboyans Victor, Baigent Colin, Collet Jean-Philippe, Dean Veronica, Delgado Victoria, Fitzsimons Donna, Gale Chris P, Grobbee Diederick E, Halvorsen Sigrun, Hindricks Gerhard, Iung Bernard, Jüni Peter, Katus Hugo A, Landmesser Ulf, Leclercq Christophe, Lettino Maddalena, Lewis Basil S, Merkely Bela, Mueller Christian, Petersen Steffen E, Petronio Anna Sonia, Richter Dimitrios J, Roffi Marco, Shlyakhto Evgeny, Simpson Iain A, Sousa-Uva Miguel, Touyz Rhian M, Zelveian Parounak H, Scherr Daniel, Jahangirov Tofig, Lazareva Irina, Shivalkar Bharati, Naser Nabil, Gruev Ivan, Milicic Davor, Petrou Petros M, Linhart Aleš, Hildebrandt Per, Hasan-Ali Hosam, Marandi Toomas, Lehto Seppo, Mansourati Jacques, Kurashvili Ramaz, Siasos Gerasimos, Lengyel Csaba, Thrainsdottir Inga S, Aronson Doron, Di Lenarda Andrea, Raissova Aigul, Ibrahimi Pranvera, Abilova Saamai, Trusinskis Karlis, Saade Georges, Benlamin Hisham, Petrulioniene Zaneta, Banu Cristiana, Magri Caroline Jane, David Lilia, Boskovic Aneta, Alami Mohamed, Liem An Ho, Bosevski Marijan, Svingen Gard Frodahl Tveitevaag, Janion Marianna, Gavina Cristina, Vinereanu Dragos, Nedogoda Sergey, Mancini Tatiana, Ilic Marina Deljanin, Fabryova Lubomira, Fras Zlatko, Jiménez-Navarro Manuel F, Norhammar Anna, Lehmann Roger, Mourali Mohamed Sami, Ural Dilek, Nesukay Elena, Chowdhury Tahseen Ahmad, ESC Scientific Document Group Aug 31;2020 European Heart Journal. 41(2):255–323. doi: 10.1093/eurheartj/ehz486. https://doi.org/10.1093/eurheartj/ehz486 [DOI] [PubMed] [Google Scholar]
  71. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08) Erdmann Erland, Charbonnel Bernard, Wilcox Robert G., Skene Allan M., Massi-Benedetti Massimo, Yates John, Tan Meng, Spanheimer Robert, Standl Eberhard, Dormandy John A., On behalf of the PROactive investigators Nov 1;2007 Diabetes Care. 30(11):2773–2778. doi: 10.2337/dc07-0717. https://doi.org/10.2337/dc07-0717 [DOI] [PubMed] [Google Scholar]
  72. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Zhu Huaqing, Yang Yixin, Wang Yanpeng, Li Jianmin, Schiller Peter W., Peng Tianqing. May 27;2011 Cardiovascular research. 92(1):75–84. doi: 10.1093/cvr/cvr145. https://doi.org/10.1093/cvr/cvr145 [DOI] [PubMed] [Google Scholar]
  73. MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy. Li X, Du N, Zhang Q, Li J, Chen X, Liu X, Hu Y, Qin W, Shen N, Xu C, Fang Z, Wei Y, Wang R, Du Z, Zhang Y, Lu Y. Oct;2014 Cell Death & Disease. 5(10):e1479. doi: 10.1038/cddis.2014.430. https://doi.org/10.1038/cddis.2014.430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin. Dai Beibei, Li Huaping, Fan Jiahui, Zhao Yanru, Yin Zhongwei, Nie Xiang, Wang Dao Wen, Chen Chen. Sep 4;2018 Cardiovascular diabetology. 17(1):1–7. doi: 10.1186/s12933-018-0767-z. https://doi.org/10.1186/s12933-018-0767-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. Guo Rui, Nair Sreejayan. Aug;2017 Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1863(8):2070–2077. doi: 10.1016/j.bbadis.2017.03.013. https://doi.org/10.1016/j.bbadis.2017.03.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. microRNAs in heart disease: putative novel therapeutic targets? Condorelli G., Latronico M. V.G., Dorn G. W. Jan 29;2010 European heart journal. 31(6):649–658. doi: 10.1093/eurheartj/ehp573. https://doi.org/10.1093/eurheartj/ehp573 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. microRNAs in cardiovascular diseases: current knowledge and the road ahead. Condorelli Gianluigi, Latronico Michael V., Cavarretta Elena. Jun;2014 Journal of the American College of Cardiology. 63(21):2177–2187. doi: 10.1016/j.jacc.2014.01.050. https://doi.org/10.1016/j.jacc.2014.01.050 [DOI] [PubMed] [Google Scholar]
  78. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Ucar Ahmet, Gupta Shashi K., Fiedler Jan, Erikci Erdem, Kardasinski Michal, Batkai Sandor, Dangwal Seema, Kumarswamy Regalla, Bang Claudia, Holzmann Angelika, Remke Janet, Caprio Massimiliano, Jentzsch Claudia, Engelhardt Stefan, Geisendorf Sabine, Glas Carolina, Hofmann Thomas G., Nessling Michelle, Richter Karsten, Schiffer Mario, Carrier Lucie, Napp L. Christian, Bauersachs Johann, Chowdhury Kamal, Thum Thomas. Jan;2012 Nature communications. 3(1) doi: 10.1038/ncomms2090. https://doi.org/10.1038/ncomms2090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Cai Lu, Wang Jianxun, Li Yan, Sun Xuihua, Wang Lipeng, Zhou Zhanxiang, Kang Y. James. Jun 1;2005 Diabetes. 54(6):1829–1837. doi: 10.2337/diabetes.54.6.1829. https://doi.org/10.2337/diabetes.54.6.1829 [DOI] [PubMed] [Google Scholar]
  80. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. Cai Lu, Wang Yuehui, Zhou Guihua, Chen Teresa, Song Ye, Li Xiaokun, Kang Y. James. Oct;2006 Journal of the American College of Cardiology. 48(8):1688–1697. doi: 10.1016/j.jacc.2006.07.022. https://doi.org/10.1016/j.jacc.2006.07.022 [DOI] [PubMed] [Google Scholar]
  81. Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. Fourquet Simon, Guerois Raphaël, Biard Denis, Toledano Michel B. Mar;2010 Journal of Biological Chemistry. 285(11):8463–8471. doi: 10.1074/jbc.m109.051714. https://doi.org/10.1074/jbc.m109.051714 [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. The Role of Nrf2-Mediated Pathway in Cardiac Remodeling and Heart Failure. Zhou Shanshan, Sun Wanqing, Zhang Zhiguo, Zheng Yang. 2014Oxidative Medicine and Cellular Longevity. 2014:1–16. doi: 10.1155/2014/260429. https://doi.org/10.1155/2014/260429 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Activation of Nrf2 signaling by natural products-can it alleviate diabetes? Matzinger Manuel, Fischhuber Katrin, Heiss Elke H. Nov;2018 Biotechnology advances. 36(6):1738–1767. doi: 10.1016/j.biotechadv.2017.12.015. https://doi.org/10.1016/j.biotechadv.2017.12.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Robledinos-Antón Natalia, Fernández-Ginés Raquel, Manda Gina, Cuadrado Antonio. Jul 14;2019 Oxidative Medicine and Cellular Longevity. 2019:1–20. doi: 10.1155/2019/9372182. https://doi.org/10.1155/2019/9372182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Effective treatment of diabetic cardiomyopathy and heart failure with reconstituted HDL (Milano) in mice. Aboumsallem Joseph, Muthuramu Ilayaraja, Mishra Mudit, Kempen Herman, De Geest Bart. Mar 13;2019 International Journal of Molecular Sciences. 20(6):1273. doi: 10.3390/ijms20061273. https://doi.org/10.3390/ijms20061273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Mitochondrial Dysfunction in Diabetic Cardiomyopathy: The Possible Therapeutic Roles of Phenolic Acids. Jubaidi Fatin Farhana, Zainalabidin Satirah, Mariappan Vanitha, Budin Siti Balkis. Aug 22;2020 International Journal of Molecular Sciences. 21(17):6043. doi: 10.3390/ijms21176043. https://doi.org/10.3390/ijms21176043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy. Li Chao, Li Yunlun, Gai Zhibo. Sep 20;2019 Current Protein & Peptide Science. 20(10):976–983. doi: 10.2174/1389203720666190726152847. https://doi.org/10.2174/1389203720666190726152847 [DOI] [PubMed] [Google Scholar]

Articles from The Brown Journal of Hospital Medicine are provided here courtesy of Department of Medicine of Alpert Medical School of Brown University

RESOURCES